Alphamab Oncology (9966) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Wuxi Biologics (Cayman), Inc.

3SBio, Inc.

Alphamab Oncology

CSPC Pharmaceutical Group Ltd.

Sirnaomics Ltd.

AIM Vaccine Co., Ltd.

Zai Lab Ltd.

Ascentage Pharma Group International Co., Ltd.

Laekna, Inc.

Beijing Lüzhu Biotechnology Co., Ltd.

Genscript Biotech Corp.

Why is Alphamab Oncology ?

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 2.31%

Poor long term growth as Operating profit has grown by an annual rate 23.73% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -19.37

Flat results in Dec 25

PRE-TAX PROFIT(Q) At HKD -148.36 MM has Fallen at -164.74%
NET PROFIT(Q) At HKD -148.36 MM has Fallen at -164.74%
CASH AND EQV(HY) Lowest at HKD 1,504 MM

With ROE of 12.42%, it has a Expensive valuation with a 4.28 Price to Book Value

Over the past year, while the stock has generated a return of 4.12%, its profits have risen by 208.3% ; the PEG ratio of the company is 0.2

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Alphamab Oncology for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Alphamab Oncology

4.12%

3.35

68.17%

Hang Seng Hong Kong

8.76%

0.45

19.63%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

439.98%

EBIT Growth (5y)

23.73%

EBIT to Interest (avg)

-19.37

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.76

Sales to Capital Employed (avg)

0.18

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.79%

ROE (avg)

2.31%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.28

EV to EBIT

35.28

EV to EBITDA

25.60

EV to Capital Employed

13.61

EV to Sales

8.48

PEG Ratio

0.17

Dividend Yield

ROCE (Latest)

38.57%

ROE (Latest)

12.42%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

OPERATING CASH FLOW(Y)

Highest at HKD 191.06 MM

RAW MATERIAL COST(Y)

Fallen by -163.59% (YoY

-8What is not working for the Company

PRE-TAX PROFIT(Q)

At HKD -148.36 MM has Fallen at -164.74%

NET PROFIT(Q)

At HKD -148.36 MM has Fallen at -164.74%

CASH AND EQV(HY)

Lowest at HKD 1,504 MM

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.34 times

NET SALES(Q)

Fallen at -46.61%

Here's what is working for Alphamab Oncology

Operating Cash Flow

Highest at HKD 191.06 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

Raw Material Cost

Fallen by -163.59% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

At HKD 36.15 MM has Grown at 6.32%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)

Here's what is not working for Alphamab Oncology

Pre-Tax Profit

At HKD -148.36 MM has Fallen at -164.74%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (HKD MM)

Net Profit

At HKD -148.36 MM has Fallen at -164.74%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (HKD MM)

Net Sales

Fallen at -46.61%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (HKD MM)

Cash and Eqv

Lowest at HKD 1,504 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Inventory Turnover Ratio

Lowest at 1.34 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio